Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib PK and Tolerance in Advanced Solid Tumors
NCT02752516Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anlotinib in solid tumor (advanced stage), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Peak Plasma Concentration up to 18 Days, Peak time up to 18 Days and 4 more. Status: unknown.
02
Drugs
anlotinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02752516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752516.